Xilio Therapeutics, Inc. (XLO )

Currency in USD Disclaimer
$1.28 +$0.34 (36.46%)
Closed 12/20/2024
$0.84
$1.28
$0.5
$1.93

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol XLO
  • Company Xilio Therapeutics, Inc.
  • Price $1.28
  • Changes Percentage 36.46
  • Change 0.342
  • Day Low $0.84
  • Day High $1.28
  • Year High $1.93
  • Year Low $0.5
  • Market Cap $56,266,333
  • Price Avg 50 EMA (D) $1
  • Price Avg 200 EMA (D) $0.97
  • Exchange NASDAQ
  • Volume 6,694,584
  • Average Volume 298,474
  • Open $1.06
  • Previous Close $0.94
  • EPS -1.55
  • PE -0.83
  • Earnings Announcement 2025-02-26 12:00:00
  • Shares Outstanding $43,958,073

Company brief: XILIO THERAPEUTICS, INC. (XLO )

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

XLO Corporation News

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

December 19, 2024 at 12:30 pm ET

globenewswire.com -- Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities...

Income Statement